Xeris Biopharma Holdings, Inc. (XERS)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Product revenue, net | 71,539 | 60,119 | 54,268 | 48,065 |
| Selling, general and administrative | 44,393 | 44,018 | 44,969 | 39,993 |
| Research and development | 8,055 | 7,753 | 5,888 | 5,759 |
| Cost of goods sold | 11,898 | 8,728 | 13,593 | 7,790 |
| Amortization of intangible assets | 2,711 | 2,710 | 2,711 | 2,710 |
| Total costs and expenses | 67,057 | 63,209 | 67,161 | 56,252 |
| Income (loss) from operations | 4,482 | -3,090 | -12,893 | -8,187 |
| Debt refinancing costs | - | - | - | - |
| Interest and other income | 948 | 1,175 | 1,197 | 1,291 |
| Interest expense | 7,358 | 7,305 | 7,786 | 7,964 |
| Change in fair value of warrants | - | - | - | -3 |
| Change in fair value of contingent value rights | - | - | -420 | -601 |
| Total other expense | -6,410 | -6,130 | -6,169 | -6,069 |
| Net loss before income taxes | -1,928 | -9,220 | -19,062 | -14,256 |
| Income tax benefit | - | - | -3,324 | 749 |
| Net loss | -1,928 | -9,220 | -15,738 | -15,005 |
| Other comprehensive income (loss), foreign currency transaction and translation gain (loss) arising during period, net of tax | 1 | - | - | 1 |
| Unrealized gains (losses) on investments | - | - | 15 | 5 |
| Comprehensive loss | -1,927 | -9,220 | -15,723 | -14,999 |
| Net loss per common share - basic (in dollars per share) | -0.01 | -0.06 | -0.11 | -0.1 |
| Net loss per common share - diluted (in dollars per share) | -0.01 | -0.06 | -0.11 | -0.1 |
| Weighted average common shares outstanding - basic (in shares) | 159,459,413 | 152,445,935 | 148,993,823 | 148,345,549 |
| Weighted average common shares outstanding - diluted (in shares) | 159,459,413 | 152,445,935 | 148,993,823 | 148,345,549 |